
ACR Journals On Air
The Power of the Negative Study
Feb 6, 2024
Dr. David R. Jayne discusses his study on an anti-CD40 antibody in lupus nephritis, highlighting the power of negative studies. They talk about challenges in conducting trials, measurement of anti-drug antibodies, embracing failures in science, and the importance of publishing negative results.
33:19
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Negative studies can provide valuable insights into the challenges of conducting clinical trials.
- The 180 milligram dose of BI655064 showed the best efficacy-safety trade-off in reducing proteinuria and anti-double-stranded DNA antibodies in lupus nephritis patients.
Deep dives
The drug BI655064 targets the CD40 CD40 ligand pathway to treat lupus nephritis
BI655064 is a second-generation humanized antagonistic anti-CD40 monoclonal antibody designed to block the CD40 CD40 ligand interaction. It has shown promise in reducing proteinuria and improving clinical endpoints in lupus nephritis patients. Unlike the prior agent BG9588, BI655064 does not cause thrombotic events and has shown effectiveness in reducing anti-double-stranded DNA antibodies.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.